A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
Completed
AbbVie
Phase 2
This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and
ABBV-599 (ELS plus upadacitinib [UPA]) vs placebo on a background of conventional synthetic
disease-modifying anti-rheumatic drugs (csDMARDs) for the treatment of signs and symptoms of
rheumatoid arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs
(bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with moderately to
severely active RA and to define optimal dose for further development.
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
Terminated
AbbVie
Phase 2
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy
of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in
participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
Active, not recruiting
AbbVie
Phase 2
The main objective of this study is to evaluate the safety and efficacy of elsubrutinib,
upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of Systemic
Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to
define doses for further development.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
